Proton pump inhibitors and the risk of colorectal cancer

被引:0
|
作者
Kawada, Tomoyuki [1 ]
机构
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Tokyo, Japan
关键词
Proton pump inhibitor; Colorectal cancer; Risk assessment;
D O I
10.1016/j.clinre.2021.101730
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页数:1
相关论文
共 50 条
  • [41] Proton pump inhibitors and infection risk
    Palencia-Herrejon, Eduardo
    Sanchez Artola, Beatriz
    Escobar Rodriguez, Ismael
    Gomez-Lus Centelles, Maria Luisa
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2011, 24 (01) : 4 - 12
  • [42] Proton pump inhibitors and tuberculosis risk
    Yates, T. A.
    Tomlinson, L. A.
    Douglas, I. J.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2020, 24 (03) : 353 - 354
  • [43] Proton Pump Inhibitors: Risk for Myopathy?
    Colmenares, Evan W.
    Pappas, Ashley L.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (01) : 66 - 71
  • [44] Proton pump inhibitors and risk of dementia
    Wijarnpreecha, Karn
    Thongprayoon, Charat
    Panjawatanan, Panadeekarn
    Ungprasert, Patompong
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (12) : 1 - 6
  • [45] A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival
    Graham, C.
    Orr, C.
    Bricks, C. S.
    Hopman, W. M.
    Hammad, N.
    Ramjeesingh, R.
    CURRENT ONCOLOGY, 2016, 23 (06) : E583 - E588
  • [47] Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer
    Brusselaers, Nele
    Lagergren, Jesper
    Engstrand, Lars
    CANCER EPIDEMIOLOGY, 2019, 62
  • [48] PROTON PUMP INHIBITORS AND RISK OF GASTRIC CANCER: A RETROSPECTIVE COHORT STUDY
    Choi, J.
    Hong, K. S.
    Kang, S. J.
    Kim, J. S.
    HELICOBACTER, 2013, 18 : 111 - 111
  • [49] Proton pump inhibitors and gastric cancer
    Waldum, Helge L.
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2016, 136 (01) : 13 - +
  • [50] Proton pump inhibitors and cancer therapy
    Blanchet, Auriane
    Patry, Charly
    Sorrieul, Jeremy
    Robert, Julien
    Devys, Catherine
    ACTUALITES PHARMACEUTIQUES, 2023, 62 (626): : 39 - 41